Pages that link to "Q28385366"
Jump to navigation
Jump to search
The following pages link to Mechanisms of action of therapeutic antibodies for cancer (Q28385366):
Displaying 30 items.
- Influence of immunoglobulin isotype on therapeutic antibody function (Q26772080) (← links)
- Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. (Q33708995) (← links)
- Prospects for gene-engineered T cell immunotherapy for solid cancers. (Q34507561) (← links)
- High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display (Q36089600) (← links)
- A monoclonal antibody against KCNK9 K( ) channel extracellular domain inhibits tumour growth and metastasis (Q36548721) (← links)
- Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen. (Q37014400) (← links)
- Discovery of cell surface vimentin targeting mAb for direct disruption of GBM tumor initiating cells (Q37687763) (← links)
- Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth (Q37689046) (← links)
- Targets, Toxins, and T Cells--a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas (Q38598544) (← links)
- Antibody Engineering for Pursuing a Healthier Future (Q38731632) (← links)
- Antigen-specific impairment of adoptive T-cell therapy against cancer: players, mechanisms, solutions and a hypothesis (Q38869740) (← links)
- Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. (Q38889427) (← links)
- Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines (Q39189908) (← links)
- Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1. (Q41573532) (← links)
- Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion (Q42081044) (← links)
- Escherichia coli surface display for the selection of nanobodies (Q42770832) (← links)
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'. (Q46527001) (← links)
- CAR-T cells and combination therapies: What's next in the immunotherapy revolution? (Q47285613) (← links)
- Neuro-ophthalmic side effects of molecularly targeted cancer drugs (Q47625145) (← links)
- Bispecific antibodies: design, therapy, perspectives (Q49195146) (← links)
- Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy (Q49592680) (← links)
- Immunotherapeutics for the treatment of prostate cancer: a patent landscape based on key therapeutic mechanisms of actions. (Q49951814) (← links)
- Monoclonal antibodies in cancer immunotherapy (Q57476468) (← links)
- Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies (Q58724935) (← links)
- Paradoxical CD4 Lymphopenia in Autoimmune Lymphoproliferative Syndrome (ALPS). (Q64892906) (← links)
- Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates (Q90053326) (← links)
- Considerations for the Design of Antibody-Based Therapeutics (Q92585782) (← links)
- Blocking Extracellular Chaperones to Improve Cardiac Regeneration (Q96304759) (← links)
- Simultaneous Monitoring and Comparison of Multiple Product Quality Attributes for Cell Culture Processes at Different Scales Using a LC/MS/MS Based Multi-Attribute Method (Q98216476) (← links)
- Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy (Q103028799) (← links)